AI Article Synopsis

  • * In a mouse study, although mutant IDH1 alone didn't transform blood cells, it significantly sped up the development of leukemia when combined with a gene called HoxA9, showcasing its potential oncogenic effects.
  • * Researchers discovered an inhibitor that specifically targets mutant IDH1, reducing 2HG levels and effectively blocking the growth of leukemia cells from patients with IDH1 mutations, indicating it could be a valuable treatment option.

Article Abstract

Mutations in the metabolic enzymes isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) are frequently found in glioma, acute myeloid leukemia (AML), melanoma, thyroid cancer, and chondrosarcoma patients. Mutant IDH produces 2-hydroxyglutarate (2HG), which induces histone- and DNA-hypermethylation through inhibition of epigenetic regulators. We investigated the role of mutant IDH1 using the mouse transplantation assay. Mutant IDH1 alone did not transform hematopoietic cells during 5 months of observation. However, mutant IDH1 greatly accelerated onset of myeloproliferative disease-like myeloid leukemia in mice in cooperation with HoxA9 with a mean latency of 83 days compared with cells expressing HoxA9 and wild-type IDH1 or a control vector (167 and 210 days, respectively, P = .001). Mutant IDH1 accelerated cell-cycle transition through repression of cyclin-dependent kinase inhibitors Cdkn2a and Cdkn2b, and activated mitogen-activated protein kinase signaling. By computational screening, we identified an inhibitor of mutant IDH1, which inhibited mutant IDH1 cells and lowered 2HG levels in vitro, and efficiently blocked colony formation of AML cells from IDH1-mutated patients but not of normal CD34(+) bone marrow cells. These data demonstrate that mutant IDH1 has oncogenic activity in vivo and suggest that it is a promising therapeutic target in human AML cells.

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2013-03-491571DOI Listing

Publication Analysis

Top Keywords

mutant idh1
32
mutant
9
idh1
9
human aml
8
myeloid leukemia
8
aml cells
8
cells
6
idh1 promotes
4
promotes leukemogenesis
4
leukemogenesis vivo
4

Similar Publications

The mesenchymal transformations of infiltrating gliomas are uncommon events. This is particularly true of IDH-mutant astrocytomas and oligodendrogliomas, in which mesenchymal transformation is exceedingly rare. oligosarcoma is a newly recognized methylation class (MC) that represents transformed 1p/19q co-deleted oligodendrogliomas, but recent studies indicate it may be non-specific.

View Article and Find Full Text PDF

Long-term survival after local immunotherapy for malignant gliomas: a retrospective study with 20 years follow-up.

BMC Immunol

December 2024

Department of Neurosurgery/Neuro-Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.

Purpose: Immunotherapy is a promising treatment for cancers but should be optimized for malignant gliomas. Because of immune privilege feature of the brain, local administration of immunotherapy may be a promising strategy for malignant glioma treatment. Identification of patients who may benefit from local immunotherapy is essential.

View Article and Find Full Text PDF

The term chondrosarcoma refers to a rare and heterogeneous group of malignant cartilaginous tumors that are typically resistant to chemotherapy and radiotherapy. Metastatic chondrosarcoma has a poor prognosis, and effective systemic therapies are lacking. Isocitrate dehydrogenase (IDH) mutations represent a potential therapeutic target, but IDH inhibitors alone have shown limited clinical efficacy to date.

View Article and Find Full Text PDF

Background: Isocitrate dehydrogenase (IDH) gene alterations and acute myeloid leukemia (AML) treatment results remain controversial. This study reviews the literature on IDH mutations in AML to determine the foundation of individualized therapy and improve effectiveness, survival time, and recurrence rate.

Methods: Seven English and 2 Chinese databases were searched for literature on IDH mutations and AML outcomes.

View Article and Find Full Text PDF

Prognostic value of immunohistochemical staining for H3K27me3 and EZH2 in astrocytoma, IDH-mutant.

J Neurooncol

December 2024

Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima City, Hiroshima, 734-8551, Japan.

Article Synopsis
  • H3K27 trimethylation (H3K27me3), regulated by EZH2, plays a critical role in gene expression and is a key diagnostic marker for certain brain tumors, but its implications in astrocytoma with IDH mutation are unclear.
  • A study involving 33 patients analyzed the correlation between immunohistochemical markers (including H3K27me3, EZH2) and patient outcomes like overall survival (OS) and progression-free survival (PFS).
  • Results indicated that H3K27me3 positivity, particularly when combined with EZH2 positivity, was associated with poorer survival rates, suggesting it may serve as a significant prognostic factor for astrocytoma, IDH
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!